title: Ellipticine derivative induces potent cytostatic effect in acute myeloid leukaemia cells.
abstract: A panel of novel ellipticine isomers were designed and synthesised with the aim of evaluating their anti-cancer effects on selected leukaemia cell lines. A preliminary NCI 60-cell screen demonstrated that these compounds display promising anti-tumour activity across a number of different cell types. We have consequently examined the effect of these derivatives in detail on the Acute Myeloid Leukaemia (AML) cell line, MV4-11. Cell cycle analyses revealed that the compounds had a range of distinctive cell cycle effects. 7-Hydroxyisoellipticine showed the most promise with respect to cytostatic activity. We demonstrated that this compound inhibited proliferation of leukaemia cells by preventing cells from progressing from G2 phase into mitosis over a period of 24 h at a concentration of 5 μM. Our research suggests that this is mediated by an induction of reactive oxygen species (ROS), which in turn activates the DNA damage response pathway. As a result of the activation of p53, cyclin B1 is inhibited. The induction of this pathway leads to apoptosis which is seen at 48 h using the same dose of 7-hydroxyisoellipticine. This study provides for the first time detailed cellular information on the potential use of isoellipticines as chemotherapeutic agents.
authors.affiliation: School of Biochemistry and Cell Biology, University College Cork, College Road, Cork, Ireland.
authors.forename: E G
authors.initials: EG
authors.lastname: Russell
authors.forename: E C
authors.initials: EC
authors.lastname: O'Sullivan
authors.forename: C M
authors.initials: CM
authors.lastname: Miller
authors.forename: J
authors.initials: J
authors.lastname: Stanicka
authors.forename: F O
authors.initials: FO
authors.lastname: McCarthy
authors.forename: T G
authors.initials: TG
authors.lastname: Cotter
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D054697:Cytostatic Agents / Q000494:pharmacology*; D004611:Ellipticines / Q000494:pharmacology*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D017382:Reactive Oxygen Species / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D054697:Cytostatic Agents; D004611:Ellipticines; D017382:Reactive Oxygen Species; D016159:Tumor Suppressor Protein p53
references.citation: FASEB J. 2003 Mar;17(3):349-68
references.pmid: 12631575
references.citation: Mol Cell Biol. 2009 May;29(10):2828-40
references.pmid: 19273588
references.citation: Free Radic Biol Med. 2003 May 15;34(10):1333-42
references.pmid: 12726921
references.citation: Mol Cell Biochem. 1999 Mar;193(1-2):137-48
references.pmid: 10331650
references.citation: Biochem Biophys Res Commun. 2002 May 17;293(4):1248-53
references.pmid: 12054510
references.citation: Cell Death Differ. 1999 Feb;6(2):99-104
references.pmid: 10200555
references.citation: Anticancer Res. 1999 Jul-Aug;19(4B):3099-108
references.pmid: 10652599
references.citation: Oncogene. 2014 Dec 11;33(50):5716-28
references.pmid: 24317508
references.citation: J Nat Prod. 2012 Mar 23;75(3):378-84
references.pmid: 22148260
references.citation: Anticancer Drugs. 2005 Aug;16(7):789-95
references.pmid: 16027529
references.citation: Am J Hematol. 1977;3:209-18
references.pmid: 341697
references.citation: Oncogene. 2003 Jul 17;22(29):4478-87
references.pmid: 12881704
references.citation: Free Radic Res. 2001 Oct;35(4):405-16
references.pmid: 11697137
references.citation: Org Biomol Chem. 2012 Oct 21;10(39):7912-21
references.pmid: 22940706
references.citation: Br J Cancer. 2004 Nov 15;91(10):1808-12
references.pmid: 15505622
references.citation: Toxicology. 2011 Nov 18;289(2-3):91-102
references.pmid: 21843585
references.citation: Biochem J. 1997 Aug 15;326 ( Pt 1):1-16
references.pmid: 9337844
references.citation: Arch Biochem Biophys. 2001 Aug 15;392(2):311-20
references.pmid: 11488607
references.citation: Oncogene. 1999 Dec 13;18(53):7644-55
references.pmid: 10618704
references.citation: Environ Mol Mutagen. 1999;33(2):144-52
references.pmid: 10217068
references.citation: J Cell Physiol. 2005 Nov;205(2):270-7
references.pmid: 15887249
references.citation: Cancer Res. 2010 Dec 1;70(23):9865-74
references.pmid: 21118972
references.citation: Cancer Cell. 2006 Sep;10(3):175-6
references.pmid: 16959608
references.citation: Mol Cancer Ther. 2004 Apr;3(4):489-97
references.pmid: 15078993
references.citation: Free Radic Biol Med. 2008 Apr 15;44(8):1529-35
references.pmid: 18275858
references.citation: Biophys J. 1993 Nov;65(5):1767-74
references.pmid: 8298010
references.citation: Biochim Biophys Acta. 1978 Jun 22;519(1):23-30
references.pmid: 566561
references.citation: J Biol Chem. 2010 May 7;285(19):14217-28
references.pmid: 20220133
references.citation: Jpn J Cancer Res. 1995 Sep;86(9):819-27
references.pmid: 7591958
references.citation: Circ Res. 2001 Apr 13;88(7):648-50
references.pmid: 11304484
references.citation: Org Biomol Chem. 2013 Feb 28;11(8):1334-44
references.pmid: 23314103
references.citation: DNA Repair (Amst). 2004 Aug-Sep;3(8-9):959-67
references.pmid: 15279782
references.citation: J Mol Biol. 1961 Feb;3:18-30
references.pmid: 13761054
references.citation: J Med Chem. 1981 Mar;24(3):289-95
references.pmid: 7265115
references.citation: J Med Chem. 2005 Oct 6;48(20):6194-201
references.pmid: 16190746
references.citation: Biochim Biophys Acta. 2014 Sep;1843(9):1865-74
references.pmid: 24769357
references.citation: Baillieres Clin Haematol. 1996 Mar;9(1):147-59
references.pmid: 8730555